

RESEARCH ARTICLE

Open Access

NDM-1 Metallo- β -Lactamase and ArmA 16S rRNA methylase producing *Providencia rettgeri* clinical isolates in Nepal

Tatsuya Tada¹, Tohru Miyoshi-Akiyama¹, Rajan K Dahal³, Manoj K Sah³, Hiroshi Ohara², Kayo Shimada¹, Teruo Kirikae^{1*} and Bharat M Pokhrel³

Abstract

Background: Drug-resistant *Providencia rettgeri* producing metallo- β -lactamase and 16S rRNA methylase has been reported in several countries. We analyzed *P. rettgeri* clinical isolates with resistance to carbapenems and aminoglycosides in a hospital in Nepal.

Methods: Five clinical isolates of multidrug-resistant *P. rettgeri* were obtained in a hospital in Nepal. Antimicrobial susceptibilities were determined using the microdilution method and entire genomes were sequenced to determine drug-resistant genes. Epidemiological analysis was performed by pulsed-field gel electrophoresis.

Results: Four of the 5 isolates were resistant to carbapenems (imipenem and meropenem), with MICs ≥ 16 mg/L, with the remaining isolate showing intermediate resistance to imipenem, with an MIC of 2 mg/L and susceptibility to meropenem with an MIC ≤ 1 mg/L. All 5 isolates had *bla*_{VEB-1}. Of the 4 carbapenem-resistant strains, 3 had *bla*_{NDM-1} and 1 had *bla*_{OXA-72}. All isolates were highly resistant to aminoglycosides (MICs $\geq 1,024$ mg/L) and harbored *armA*. As the result of pulsed-field gel electrophoresis pattern analysis in the 5 *P. rettgeri* isolates, 4 had identical PFGE patterns and the fifth showed 95.7% similarity.

Conclusions: This is the first report describing multidrug-resistant *P. rettgeri* strains harboring *bla*_{NDM-1} or *bla*_{OXA-72} and *armA* isolated from patients in Nepal.

Keywords: NDM-1, OXA-72, 16S rRNA methylase, *Providencia rettgeri*, Molecular epidemiology

Background

Providencia rettgeri has been associated with hospital acquired infections, including catheter-related urinary tract infections, bacteremia, skin infections, diarrhea, and gastroenteritis [1,2]. To date, there have been 5 reports of *P. rettgeri* isolates harboring metallo- β -lactamase (MBL) encoding genes, including IMP-type MBL producers in Japan [3,4]; VIM-type MBL, PER-1 extended-spectrum β -lactamase (ESBL) and 16S rRNA methylase ArmA in Korea [5]; and NDM-type MBL in Israel [6] and Brazil [7].

NDM-type MBL was initially identified in *Klebsiella pneumoniae* and *Escherichia coli* in 2009 in Sweden [8].

Since then, NDM-1-producing *Enterobacteriaceae* have been isolated in various parts of the world [9,10].

Exogenously acquired 16S rRNA methylase genes responsible for very high levels of resistance to various aminoglycosides are widely distributed among *Enterobacteriaceae* and glucose-nonfermentative microbes [11]. Gram-negative pathogens producing 16S rRNA methylase ArmA have been isolated in various countries [11].

Although co-production of several resistance determinants is not rare in *Enterobacteriaceae* [12-16], it is less common in *P. rettgeri* [5]. We describe here *P. rettgeri* clinical isolates from Nepal that produce carbapenemase (NDM-1 or OXA-72) and 16S rRNA methylase (ArmA).

* Correspondence: tkirikae@ri.ncgm.go.jp

¹Department of Infectious Diseases, Research Institute, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku, Tokyo 162-8655, Japan
Full list of author information is available at the end of the article

Table 1 Summary of the characteristics of the 5 *P. rettgeri* strains, including antimicrobial resistance profiles and resistant genes

Strains	Tissue sources	Infection	MIC (mg/L)														Antibiotics resistant genes	
			PIP	TZP	CAZ	FEP	IPM	DPM	MEM	ATM	ABK	AMK	GEN	CIP	CST	FOF		TIG
IOMTU1	Pus	SSI	1,024	512	>1,024	64	32	16	64	1,024	>1,024	>1,024	>1,024	128	>128	512	4	<i>bla</i> _{NDM-1} , <i>bla</i> _{OXA-10} , <i>bla</i> _{VEB-1} , <i>bla</i> _{TEM-1} , <i>bla</i> _{ADC-67} , <i>armA</i> , <i>aadA1</i> , <i>aadA2</i>
IOMTU4	Sputum	NLRTI	1,024	128	>1,024	256	16	16	32	1,024	>1,024	>1,024	>1,024	>256	>128	512	4	<i>bla</i> _{OXA-72} , <i>bla</i> _{OXA-10} , <i>bla</i> _{VEB-1} , <i>bla</i> _{TEM-1} , <i>bla</i> _{ADC-67} , <i>armA</i> , <i>aadA1</i>
IOMTU91	Sputum	NLRTI	>1,024	1,024	>1,024	1,024	64	32	64	1,024	>1,024	>1,024	>1,024	256	128	128	4	<i>bla</i> _{NDM-1} , <i>bla</i> _{OXA-10} , <i>bla</i> _{VEB-1} , <i>bla</i> _{TEM-1} , <i>bla</i> _{ADC-67} , <i>armA</i> , <i>aadA1</i>
IOMTU94	Pus	SSI	1,024	4	>1,024	256	2	1	1	>1,024	1,024	1,024	>1,024	256	>128	1,024	4	<i>bla</i> _{OXA-10} , <i>bla</i> _{VEB-1} , <i>bla</i> _{TEM-1} , <i>bla</i> _{ADC-67} , <i>armA</i> , <i>aadA1</i>
IOMTU99	Sputum	NLRTI	>1,024	512	>1,024	128	64	32	64	1,024	>1,024	>1,024	>1,024	>256	>128	1,024	4	<i>bla</i> _{NDM-1} , <i>bla</i> _{VEB-1} , <i>bla</i> _{OXA-10} , <i>bla</i> _{TEM-1} , <i>bla</i> _{ADC-67} , <i>armA</i> , <i>aadA1</i>

SSI, surgical site infection; NLRTI, nosocomial lower respiratory tract infection PIP, piperacillin; TZP, piperacillin/tazobactam; CAZ, ceftazidime; FEP, cefepime; IPM, imipenem; DPM, doripenem; MEM, meropenem; ATM, aztreonam; ABK, arbekacin; AMK, amikacin; GEN, gentamicin; CIP, ciprofloxacin; CST, colistin; FOF, fosfomicin; TIG, tigecycline.

Methods

Bacterial strains

Five *P. rettgeri* clinical isolates were obtained from May to July 2012 from 5 patients at Tribhuvan University Teaching Hospital in Kathmandu, Nepal. Three isolates were from sputum and 2 from pus at surgical sites. Samples were obtained as part of standard patient care. Phenotypical identification [17] was confirmed by API 32GN (BioMérieux, Mercy l'Etoile, France) and 16S rRNA sequencing (1,497 bp) [18,19].

Antimicrobial susceptibilities

MICs were determined using the microdilution method, according to the guidelines of the Clinical Laboratory Standards Institute (CLSI) [20]. Breakpoints to antibiotics were determined. The modified Hodge test, the meropenem-sodium mercaptoacetic acid double-disk synergy test (Eiken Chemical, Tokyo, Japan) and E-test (imipenem/EDTA) (AB Biodisk, Solna, Sweden) were performed.

Entire genome sequencing

The entire genomes of these isolates were extracted and sequenced by MiSeq (Illumina, San Diego, CA). CLC genomics workbench version 5.5 (CLC bio, Tokyo, Japan) was used for de novo assembly of reads and to search for 923 drug-resistance genes, including genes encoding β -lactamases, 16S rRNA methylases and aminoglycoside-acetyl/adenyltransferases; point mutations in the *gyrA*, *parC* and *pmrCAB* operons; and point mutations in the *fos* genes, including *fosA*, *fosA2*, *fosA3*, *fosC* and *fosC2*.

Pulsed-field gel electrophoresis (PFGE) and southern hybridization

PFGE analysis was performed as described [3]. An 813 bp probe for *bla*_{NDM-1} was synthesized by PCR amplification using the primers 5'-atggaattgcccaatattatg-cac-3' (forward) and 5'-tcagcgcagcttgcggccatgcggg-3' (reverse), and a 780 bp probe for *bla*_{OXA-72} was synthesized using the primers 5'-agtttctcagtcgatgttcattc-3' (forward) and 5'-agaaccagacattccttcttcttctc-3' (reverse). Southern hybridization to detect *bla*_{NDM-1} and *bla*_{OXA-72} was performed using these probes, which were detected using DIG High Prime DNA labeling and detection starter kit II (Roche Diagnostics, Mannheim, Germany).

Nucleotide sequence accession numbers

The nucleotide sequences surrounding *bla*_{NDM-1} and *bla*_{OXA-72} have been deposited in GenBank with the accession number AB828598 and AB857844, respectively.

Ethical approval

The study protocol was reviewed and approved by the Institutional Review Board of the Institute of Medicine,

Tribhuvan University (ref. 6-11-E) and the Biosafety Committee, National Center for Global Health and Medicine (approval number: 23-M-49).


Results

Antimicrobial susceptibilities

Four of the 5 isolates were resistant to carbapenems (doripenem, imipenem and meropenem) and piperacillin/tazobactam, whereas the fifth was susceptible to piperacillin/tazobactam, doripenem and meropenem and showed intermediate resistance to imipenem (Table 1). All 5 isolates were highly resistant to cephalosporins (ceftazidime and cefepime), aztreonam, aminoglycosides (arbakacin, amikacin and gentamicin), ciprofloxacin, colistin and fosfomycin, and all 5 showed intermediate resistance to tigecycline. The four isolates resistant to carbapenems were negative with the modified Hodge test, but three of the four isolates were positive with the meropenem-sodium mercaptoacetic acid double-disk synergy test and E-test/EDTA.

Drug-resistant genes

All 5 isolates tested had several genes associated with β -lactam and aminoglycoside-resistance (Table 1). These isolates had *bla*_{VEB-1}, *bla*_{OXA-10}, *bla*_{TEM-1}, *bla*_{ADC-67} (*ampC*), *armA* and *aadA1*; 3 had *bla*_{NDM-1}; and 1 had *bla*_{OXA-72}. None of these isolates had any other β -lactamase encoding genes, including the class A genes *bla*_{SHVs} and *bla*_{CTX-Ms}; the class B genes *bla*_{AIM}, *bla*_{DIM}, *bla*_{FIM}, *bla*_{GIM}, *bla*_{IMP}s, *bla*_{IND}s, *bla*_{KHM}, *bla*_{SIM}, *bla*_{SMB}, *bla*_{SPM}, *bla*_{TMB}s, and *bla*_{VIM}s; or the class D gene *bla*_{OXA}s except for *bla*_{OXA-10} and *bla*_{OXA-72}. None had other genes encoding 16S rRNA methylases or aminoglycoside acetyl/adenyltransferases. All 5 isolates had point mutations in the quinolone-resistance-determining regions of *gyrA* and *parC*, with amino acid substitutions of S83I and D87E in GyrA and S80I in ParC, but none had any mutations in the *pmrCAB* operon and *fos* genes. All sequences of the drug-resistant genes tested were identical to those registered in GenBank.



PFGE and southern hybridization

Of the 5 *P. rettgeri* isolates, 4 had identical PFGE patterns and the fifth showed 95.7% similarity (Figure 1). Three of these isolates had a plasmid harboring *bla*_{NDM-1} and one had a plasmid harboring *bla*_{OXA-72}, with plasmid sizes ranging from 9.42 to 23.1 kbp (data not shown).

Genomic structures surrounding *bla*_{NDM-1} and *bla*_{OXA-72}

The genetic environments surrounding *bla*_{NDM-1} (Accession no. AB828598) was *bla*_{NDM-1}-*ble*_{MBL}-*trpF*-*dsbC*-*cutA1*. All 3 isolates harboring *bla*_{NDM-1} (IOMTU1, 91 and 99) had the same genetic environments. The *bla*_{OXA-72} gene was flanked by conserved inverted repeats at the XerC/XerD binding sites [21], indicating mobilization by site-specific recombination mechanisms. The *rep1* gene was located downstream of *bla*_{OXA-72} (Accession no. AB857844).

Discussion

The relatively high MICs to piperacillin/tazobactam and carbapenems of the five *P. rettgeri* isolates were likely due to the presence of *bla*_{NDM-1} or *bla*_{OXA-72}. The enzymatic activities of metallo- β -lactamases, including NDM-1, were not inhibited by tazobactam [22], a β -lactamase inhibitor, in agreement with the MIC profiles of these isolates to piperacillin/tazobactam. The high MICs of all 5 isolates to ceftazidime, cefepime and aztreonam were likely due to the presence of *bla*_{VEB-1} [23], and the presence of *armA* in these isolates was likely associated with their extremely high resistance to all aminoglycosides tested [11]. Point mutations in the quinolone-resistance-determining regions of *gyrA* and *parC* have been associated with high resistance to quinolones [24]. Point mutations in *pmrCAB* operon have been associated with the resistance of *Acinetobacter* spp. [25] and *Pseudomonas aeruginosa* [26] to polymyxin and colistin; and the presence of *fos* genes, including *fosA*, *fosA2*, *fosA3*, *fosC* and *fosC2*, has been associated with resistance to fosfomycin in Gram-negative bacteria [27-29].

Plasmids containing *bla*_{NDM-1} or *bla*_{OXA-72} may be disseminated among Gram-negative pathogens in Nepal. The genetic environments surrounding *bla*_{NDM-1} in our *P. rettgeri* strains (*bla*_{NDM-1}-*ble*_{MBL}-*trpF*-*dsbC*-*cutA1*) were also observed in other plasmids, including *A. baumannii* plasmid pAbNDM-1 from China (Accession no. JN377410), *Citrobacter freundii* plasmid pYE315203 from China (Accession no. JX254913), *E. coli* plasmid pNDM102337 from Canada (Accession no. JF714412), *K. pneumoniae* plasmid pKP-NCGM18-1 from Nepal (Accession no. AB824738) [30], *K. pneumoniae* plasmids pKPX-1, pKPN5047 and pNDM-HN380 from China (Accession nos. AP012055, KC311431 and JX104760, respectively), and *P. rettgeri* plasmid pFR90 (Accession no. JQ362415) from China. In addition, the genetic structures

of OXA-72 producing *Acinetobacter* spp [31-34] and *K. pneumoniae* (Accession no. JX268653 and AB825955 deposited in 2012 and 2013, respectively) had the same genetic structure (*bla*_{OXA-72}-*rep1*) as our strain of *P. rettgeri*.

Conclusions

To our knowledge, this is the first report describing *P. rettgeri* strains harboring *bla*_{NDM-1} or *bla*_{OXA-72} and *armA* isolated from patients in Nepal. These 5 strains were highly resistant to both β -lactams and aminoglycosides and expanded in a clonal manner in the hospital.

Competing interests

The authors declare that they have no competing interest.

Authors' contributions

TT: Performed PCR and sequencing, analyzed data and drafted the manuscript. TMA: Performed entire genome sequencing. RKD and MKS: Performed drug susceptibility tests. HO: Supervised this study. KS: Performed pulsed-field gel electrophoresis and its pattern analysis. TK and BMP: Designed protocols and supervised this study. All authors read and approved the final manuscript.

Acknowledgements

The authors thank emeritus professor Masayasu Nakano, Jichi Medical University, for comments on the manuscript. This study was supported by grants [International Health Cooperation Research (23-A-301 and 24-S-5), a grant from the Ministry of Health, Labor and Welfare of Japan (H24-Shinko-Ippan-010), and JSPS KAKENHI Grant Number 24790432].

Author details

¹Department of Infectious Diseases, Research Institute, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku, Tokyo 162-8655, Japan. ²Department of International Medical-Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan. ³Department of Microbiology, Institute of Medicine, Tribhuvan University, Maharajgunj, Kathmandu, Nepal.

Received: 1 May 2013 Accepted: 27 January 2014

Published: 3 February 2014

References

1. Stock I, Wiedemann B: Natural antibiotic susceptibility of *Providencia stuartii*, *P. rettgeri*, *P. alcalifaciens* and *P. rustigianii* strains. *J Med Microbiol* 1998, **47**:629-642.
2. Yoh M, Matsuyama J, Ohnishi M, Takagi K, Miyagi H, Mori K, Park KS, Ono T, Honda T: Importance of *Providencia* species as a major cause of travellers' diarrhoea. *J Med Microbiol* 2005, **54**:1077-1082.
3. Shiroto K, Ishii Y, Kimura S, Alba J, Watanabe K, Matsushima Y, Yamaguchi K: Metallo-beta-lactamase IMP-1 in *Providencia rettgeri* from two different hospitals in Japan. *J Med Microbiol* 2005, **54**:1065-1070.
4. Nishio H, Komatsu M, Shibata N, Shimakawa K, Sueyoshi N, Ura T, Satoh K, Toyokawa M, Nakamura T, Wada Y, Orita T, Kofuku T, Yamasaki K, Sakamoto M, Kinoshita S, Aihara M, Arakawa Y: Metallo-beta-lactamase-producing Gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan. *J Clin Microbiol* 2004, **42**:5256-5263.
5. Lee HW, Kang HY, Shin KS, Kim J: Multidrug-resistant *Providencia* isolates carrying *bla*_{PER-1}, *bla*_{VIM-2}, and *armA*. *J Microbiol* 2007, **45**:272-274.
6. Gefen-Halevi S, Hindiyeh MY, Ben-David D, Smolan G, Gal-Mor O, Azar R, Castanheira M, Belausov N, Rahav G, Tal I, Mendelson E, Keller N: Isolation of genetically not related *bla*_{NDM-1} positive *Providencia rettgeri* in Israel. *J Clin Microbiol* 2013, **51**:1642-1643.
7. Carvalho-Assef AP, Pereira PS, Albano RM, Beriao GC, Chagas TP, Timm LN, Da Silva RC, Falci DR, Asensi MD: Isolation of NDM-producing *Providencia rettgeri* in Brazil. *J Antimicrob Chemother.* in press.

8. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR: Characterization of a new metallo-beta-lactamase gene, *bla*_{NDM-1}, and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob Agents Chemother* 2009, **53**:5046–5054.
9. Cornaglia G, Giamarellou H, Rossolini GM: Metallo-beta-lactamases: a last frontier for beta-lactams? *Lancet Infect Dis* 2011, **11**:381–393.
10. Pillai DR, McGeer A, Low DE: New Delhi metallo-beta-lactamase-1 in Enterobacteriaceae: emerging resistance. *CMAJ* 2011, **183**:59–64.
11. Wachino J, Arakawa Y: Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: an update. *Drug Resist Updat* 2012, **15**:133–148.
12. Sheng WH, Badal RE, Hsueh PR, SMART Program: Distribution of extended-spectrum beta-Lactamases, AmpC beta-Lactamases, and carbapenemases among enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). *Antimicrob Agents Chemother* 2013, **57**:2981–2988.
13. Bueno MF, Francisco GR, O'Hara JA, de Oliveira Garcia D, Doi Y: Co-production of 16S Ribosomal RNA Methyltransferase RmtD and RmtG with KPC-2 and CTX-M-group ESBLs in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2013, **57**:2397–2400.
14. Galani I, Souli M, Panagea T, Poulakou G, Kanellakopoulou K, Giamarellou H: Prevalence of 16S rRNA methylase genes in Enterobacteriaceae isolates from a Greek university hospital. *Clin Microbiol Infect* 2012, **18**:E52–E54.
15. Zacharczuk K, Piekarska K, Szych J, Zawidzka E, Sulikowska A, Wardak S, Jagielski M, Gierczynski R: Emergence of *Klebsiella pneumoniae* coproducing KPC-2 and 16S rRNA methylase ArmA in Poland. *Antimicrob Agents Chemother* 2011, **55**:443–446.
16. Wu Q, Liu Q, Han L, Sun J, Ni Y: Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 and ArmA 16S rRNA methylase conferring high-level aminoglycoside resistance in carbapenem-resistant *Enterobacter cloacae* in China. *Diagn Microbiol Infect Dis* 2010, **66**:326–328.
17. Tang YW, Ellis NM, Hopkins MK, Smith DH, Dodge DE, Persing DH: Comparison of phenotypic and genotypic techniques for identification of unusual aerobic pathogenic gram-negative bacilli. *J Clin Microbiol* 1998, **36**:3674–3679.
18. Marchesi JR, Sato T, Weightman AJ, Martin TA, Fry JC, Hiom SJ, Dymock D, Wade WG: Design and evaluation of useful bacterium-specific PCR primers that amplify genes coding for bacterial 16S rRNA. *Appl Environ Microbiol* 1998, **64**:795–799.
19. Simmon KE, Croft AC, Petti CA: Application of SmartGene IDNS software to partial 16S rRNA gene sequences for a diverse group of bacteria in a clinical laboratory. *J Clin Microbiol* 2006, **44**:4400–4406.
20. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 9th ed. In *Approved standard M07-A9*. 8th edition. Wayne, Pa: Clinical and Laboratory Standards Institute; 2012.
21. D'Andrea MM, Giani T, D'Arezzo S, Capone A, Petrosillo N, Visca P, Luzzaro F, Rossolini GM: Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2009, **53**:3528–3533.
22. Bush K, Jacoby GA: Updated functional classification of beta-lactamases. *Antimicrob Agents Chemother* 2010, **54**:969–976.
23. Poirel L, Naas T, Guibert M, Chaibi EB, Labia R, Nordmann P: Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum beta-lactamase encoded by an *Escherichia coli* integron gene. *Antimicrob Agents Chemother* 1999, **43**:573–581.
24. Jacoby GA: Mechanisms of resistance to quinolones. *Clin Infect Dis* 2005, **41**(Suppl 2):S120–S126.
25. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA: Resistance to colistin in *Acinetobacter baumannii* associated with mutations in the PmrAB two-component system. *Antimicrob Agents Chemother* 2009, **53**:3628–3634.
26. Moskowitz SM, Ernst RK, Miller SI: PmrAB, a two-component regulatory system of *Pseudomonas aeruginosa* that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. *J Bacteriol* 2004, **186**:575–579.
27. Beharry Z, Palzkill T: Functional analysis of active site residues of the fosfomycin resistance enzyme FosA from *Pseudomonas aeruginosa*. *J Biol Chem* 2005, **280**:17786–17791.
28. Xu H, Miao V, Kwong W, Xia R, Davies J: Identification of a novel fosfomycin resistance gene (*fosA2*) in *Enterobacter cloacae* from the Salmon River, Canada. *Lett Appl Microbiol* 2011, **52**:427–429.
29. Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y: Prevalence of fosfomycin resistance among CTX-M-producing *Escherichia coli* clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. *Antimicrob Agents Chemother* 2010, **54**:3061–3064.
30. Tada T, Miyoshi-Akiyama T, Dahal RK, Mishra SK, Ohara H, Shimada K, Kirikae T, Pokhrel BM: Dissemination of multidrug-resistant *Klebsiella pneumoniae* clinical isolates with various combinations of carbapenemases (NDM-1 and OXA-72) and 16S rRNA methylases (ArmA, RmtC and RmtF) in Nepal. *Int J Antimicrob Agents* 2013, **42**:372–374.
31. Werneck JS, Picao RC, Carvalhaes CG, Cardoso JP, Gales AC: OXA-72-producing *Acinetobacter baumannii* in Brazil: a case report. *J Antimicrob Chemother* 2011, **66**:452–454.
32. Wang H, Guo P, Sun H, Wang H, Yang Q, Chen M, Xu Y, Zhu Y: Molecular epidemiology of clinical isolates of carbapenem-resistant *Acinetobacter* spp. from Chinese hospitals. *Antimicrob Agents Chemother* 2007, **51**:4022–4028.
33. Montealegre MC, Maya JJ, Correa A, Espinal P, Mojica MF, Ruiz SJ, Rosso F, Vila J, Quinn JP, Villegas MV: First identification of OXA-72 carbapenemase from *Acinetobacter pittii* in Colombia. *Antimicrob Agents Chemother* 2012, **56**:3996–3998.
34. Goic-Barisic I, Towner KJ, Kovacic A, Sisko-Kraljevic K, Tonkic M, Novak A, Punda-Polic V: Outbreak in Croatia caused by a new carbapenem-resistant clone of *Acinetobacter baumannii* producing OXA-72 carbapenemase. *J Hosp Infect* 2011, **77**:368–369.

doi:10.1186/1471-2334-14-56

Cite this article as: Tada et al.: NDM-1 Metallo-β-Lactamase and ArmA 16S rRNA methylase producing *Providencia rettgeri* clinical isolates in Nepal. *BMC Infectious Diseases* 2014 **14**:56.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

